9,700 Shares in Integer Holdings Corporation (NYSE:ITGR) Bought by Wolverine Asset Management LLC

Key Points

• Wolverine Asset Management LLC has acquired a new stake of 9,700 shares in Integer Holdings Corporation, valued at approximately $1,145,000, according to a recent SEC filing.
• Integer Holdings reported quarterly earnings showing 11.4% revenue growth and a net margin of 4.61%, although it missed EPS expectations by $0.02.
• Analysts have lowered price targets for Integer, with a consensus rating of "Moderate Buy" and an average target price of $140.25, indicating potential growth despite recent adjustments.

Wolverine Asset Management LLC acquired a new stake in shares of Integer Holdings Corporation (NYSE:ITGR - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 9,700 shares of the medical equipment provider's stock, valued at approximately $1,145,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ITGR. AdvisorNet Financial Inc acquired a new stake in Integer in the 1st quarter valued at approximately $28,000. Opal Wealth Advisors LLC acquired a new stake in shares of Integer in the 1st quarter valued at $28,000. Bessemer Group Inc. increased its holdings in shares of Integer by 73.1% in the 1st quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 125 shares during the last quarter. Sterling Capital Management LLC raised its holdings in Integer by 472.9% during the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 279 shares in the last quarter. Finally, Headlands Technologies LLC grew its holdings in shares of Integer by 1,234.8% during the first quarter. Headlands Technologies LLC now owns 1,228 shares of the medical equipment provider's stock worth $145,000 after purchasing an additional 1,136 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company's stock.

Insider Buying and Selling at Integer

In related news, Director Donald J. Spence sold 14,739 shares of the company's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the completion of the transaction, the director owned 18,781 shares of the company's stock, valued at approximately $2,260,856.78. This represents a 43.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Martin C. Maxwell sold 8,720 shares of the company's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $120.56, for a total value of $1,051,283.20. Following the sale, the director owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. The trade was a 28.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.16% of the company's stock.

Integer Price Performance

Shares of Integer stock traded up $2.38 during trading on Wednesday, hitting $109.71. 557,857 shares of the company were exchanged, compared to its average volume of 489,237. Integer Holdings Corporation has a fifty-two week low of $104.93 and a fifty-two week high of $146.36. The company has a quick ratio of 2.18, a current ratio of 3.41 and a debt-to-equity ratio of 0.72. The firm has a 50 day moving average price of $115.83 and a 200 day moving average price of $120.96. The stock has a market capitalization of $3.84 billion, a price-to-earnings ratio of 48.33, a P/E/G ratio of 0.83 and a beta of 1.02.

Integer (NYSE:ITGR - Get Free Report) last released its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.02). The firm had revenue of $476.00 million during the quarter, compared to analysts' expectations of $464.37 million. Integer had a net margin of 4.61% and a return on equity of 12.27%. Integer's revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the company posted $1.30 earnings per share. On average, equities analysts expect that Integer Holdings Corporation will post 6.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ITGR has been the subject of a number of recent research reports. KeyCorp decreased their price target on shares of Integer from $154.00 to $145.00 and set an "overweight" rating for the company in a research note on Monday, April 21st. Benchmark dropped their price objective on Integer from $150.00 to $140.00 and set a "buy" rating on the stock in a report on Friday, April 25th. Wells Fargo & Company reduced their target price on Integer from $152.00 to $132.00 and set an "overweight" rating for the company in a report on Friday, July 25th. Wall Street Zen raised shares of Integer from a "sell" rating to a "hold" rating in a research note on Monday, May 19th. Finally, Citigroup upgraded shares of Integer from a "hold" rating to a "strong-buy" rating and raised their price objective for the company from $133.00 to $140.00 in a research note on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $140.25.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.